Biblio

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

W

Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55-66.

Mansour R, El-Orfali Y, Saber A, Noun D, Youssef N, Youssef Y, Hanna-Wakim R, Dbaibo G, Abboud M, Massaad MJ. Wiskott-Aldrich syndrome in four male siblings from a consanguineous family from Lebanon. Clin Immunol. 2020:108573.

Yuan B, Zhou X, Suzuki K, Ramos-Mandujano G, Wang M, Tehseen M, Cortés-Medina LV, Moresco JJ, Dunn S, Hernández-Benítez R, et al. Wiskott-Aldrich syndrome protein forms nuclear condensates and regulates alternative splicing. Nat Commun. 2022;13(1):3646.

Pille M, Avila J, Sanchez GSanchez, Goetgeluk G, De Munter S, Jansen H, Billiet L, Weening K, Xue H, Bonte S, et al. The Wiskott-Aldrich syndrome protein is required for positive selection during T-cell lineage differentiation. Front Immunol. 2023;14:1188099.

Zheng Y, Shen P, Tong M, Li H, Ren C, Wu F, Li HY, Yang H, Cai B, Du W, et al. WISP2 downregulation inhibits the osteogenic differentiation of BMSCs in congenital scoliosis by regulating Wnt/β-catenin pathway. Biochim Biophys Acta Mol Basis Dis. 2023:166783.

Knowles BB. The Wistar Legacy to Embryonic Stem Cell Research. Monoclon Antib Immunodiagn Immunother. 2014.

Martins AR, Matias GSS, Batista VF, Miglino MA, Fratini P. Wistar rat dermis recellularization. Res Vet Sci. 2020;131:222-231.

Beutel G, Liebregts T, Böll B. [With a tumor diagnosis in the intensive care unit]. Inn Med (Heidelb). 2023.

Sun YEve, Cheng L, Hu K. With NuRD, HDACs Go "Nerdy". Dev Cell. 2014;30(1):9-10.

Xing Z, Su A, Mi L, Zhang YJ, He T, Qiu Y, Wei T, Li Z, Zhu J, Wu W. Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms. Drug Des Devel Ther. 2023;17:2909-2929.

Kakar SS, Ratajczak MZ, Powell KS, Moghadamfalahi M, Miller DM, Batra SK, Singh SK. Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells. PLoS One. 2014;9(9):e107596.

Gupta SKumar, Gohil D, Dutta D, Panigrahi GCh, Gupta P, Dalvi K, Khanka T, Yadav S, Kaushal RKumar, Chichra A, et al. Withaferin-A alleviates acute graft versus host disease without compromising graft versus leukemia effect. Int Immunopharmacol. 2023;121:110437.

Kuang Z, Bai J, Ni L, Hang K, Xu J, Ying L, Xue D, Pan Z. Withanolide B promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via ERK1/2 and Wnt/β-catenin signaling pathways. Int Immunopharmacol. 2020;88:106960.

Pietsch C, Ennuschat N, Härtel S, Liebert UG. Within-host evolution of virus variants during chronic infection with novel GII.P26-GII.26 norovirus. J Clin Virol. 2018;108:96-102.

Viinikainen K, Isohanni P, Kanerva J, Lönnqvist T, Lauronen L. Without ENMG, detecting pediatric vincristine neuropathy is a challenge. Clin Neurophysiol Pract. 2024;9:94-101.

Justice M, Carico ZM, Stefan HC, Dowen JM. A WIZ/Cohesin/CTCF Complex Anchors DNA Loops to Define Gene Expression and Cell Identity. Cell Rep. 2020;31(2):107503.

Heo SChul, Kwon YWoo, Jang IHo, Jeong GOk, Yoon JWon, Kim CDae, Kwon SMo, Bae Y-S, Kim JHo. WKYMVm-induced activation of formyl peptide receptor 2 stimulates ischemic neovasculogenesis by promoting homing of endothelial colony forming cells. Stem Cells. 2013.

Ni C-X, Qi Y, Zhang J, Liu Y, Xu W-H, Xu J, Hu H-G, Wu Q-Y, Wang Y, Zhang J-P. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway. Oncotarget. 2016.

Chi R-PAlicia, Xu X, Li J-L, Xu X, Hu G, Brown P, Willson C, Kirsanov O, Geyer C, Huang C-L, et al. WNK1 is required during male pachynema to sustain fertility. iScience. 2023;26(9):107616.

Buikema JW, Lee S, Goodyer WR, Maas RG, Chirikian O, Li G, Miao Y, Paige SL, Lee D, Wu H, et al. Wnt Activation and Reduced Cell-Cell Contact Synergistically Induce Massive Expansion of Functional Human iPSC-Derived Cardiomyocytes. Cell Stem Cell. 2020;27(1):50-63.e5.

Xin H-W, Ambe CM, Ray S, Kim B-K, Koizumi T, Wiegand GW, Hari D, Mullinax JE, Jaiswal KR, Garfield SH, et al. Wnt and the cancer niche: paracrine interactions with gastrointestinal cancer cells undergoing asymmetric cell division. J Cancer. 2013;4(6):447-57.

Y Narayanaa K, P Kumar N, Warrier S, Perumalsamy LR, Dharmarajan A. Wnt Antagonist as therapeutic targets in Ovarian Cancer. Int J Biochem Cell Biol. 2022:106191.

Visweswaran M, Schiefer L, Arfuso F, Dilley RJ, Newsholme P, Dharmarajan A. Wnt Antagonist Secreted Frizzled-Related Protein 4 Upregulates Adipogenic Differentiation in Human Adipose Tissue-Derived Mesenchymal Stem Cells. PLoS One. 2015;10(2):e0118005.

Krimpenfort P, Berns A. Wnt Down, Tumors Wind Up?. Cell. 2015;161(7):1494-1496.

Lu B, Green BA, Farr JM, Lopes FCM, Van Raay TJ. Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials. Cancers (Basel). 2016;8(9).

Pages